Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by biotech1973on Dec 02, 2019 9:27am

52 Views

Post# 30412607

RE:RE:RE:RE:RE:11/29/19 SEDAR REPORTS A NIGHTMARE!!

You ask him questions, he doesnt know. You want to get into a justofied argument ,he doesnt know . Only thing he writes is DELISTING, REGULATORS ACTION , 4 WEEKS OF CASH.Thts it. Whatever masters tell him to write.He must be sleeping right now. Is he from Asian Country?

Bullboard Posts

5 steps to mastering risk management in the stock market